WO1995017904A3 - Botulinum toxins for treating various disorders and associated pain - Google Patents

Botulinum toxins for treating various disorders and associated pain Download PDF

Info

Publication number
WO1995017904A3
WO1995017904A3 PCT/US1994/014717 US9414717W WO9517904A3 WO 1995017904 A3 WO1995017904 A3 WO 1995017904A3 US 9414717 W US9414717 W US 9414717W WO 9517904 A3 WO9517904 A3 WO 9517904A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating various
various disorders
botulinum toxins
associated pain
botulinum toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/014717
Other languages
French (fr)
Other versions
WO1995017904A2 (en
WO1995017904B1 (en
Inventor
K Roger Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22634387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1995017904(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to AU15162/95A priority Critical patent/AU688452B2/en
Priority to JP51812795A priority patent/JP3238154B2/en
Priority to CA002180011A priority patent/CA2180011C/en
Priority to EP95906674A priority patent/EP0737074B1/en
Priority to DE69427869T priority patent/DE69427869T2/en
Publication of WO1995017904A2 publication Critical patent/WO1995017904A2/en
Publication of WO1995017904A3 publication Critical patent/WO1995017904A3/en
Publication of WO1995017904B1 publication Critical patent/WO1995017904B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for relieving pain, associated with muscle contractions, a composition and a method of treating conditions such as cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretions and a method for treating smooth muscle disorders including, but not limited to, spasms in the sphincter of the cardiovascular arteriole, gastrointestinal system, urinary, gall bladder and rectum, which method comprises administering to the patient suffering from said disorder or condition a therapeutically effective amount of Botulinum toxin selected from the group consisting of Botulinum toxin types B, C, D, E, F and G.
PCT/US1994/014717 1993-12-28 1994-12-16 Botulinum toxins for treating various disorders and associated pain Ceased WO1995017904A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU15162/95A AU688452B2 (en) 1993-12-28 1994-12-16 Botulinum toxins for treating various disorders and associated pain
JP51812795A JP3238154B2 (en) 1993-12-28 1994-12-16 Botulinum toxin-containing pharmaceutical composition for reducing excessive sweating
CA002180011A CA2180011C (en) 1993-12-28 1994-12-16 Botulinum toxins for treating sweating
EP95906674A EP0737074B1 (en) 1993-12-28 1994-12-16 Botulinum toxins for treating hyperhydrosis
DE69427869T DE69427869T2 (en) 1993-12-28 1994-12-16 BOTULINUMTOXINS FOR TREATING HYPERHYDROSIS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17399693A 1993-12-28 1993-12-28
US08/173,996 1993-12-28

Publications (3)

Publication Number Publication Date
WO1995017904A2 WO1995017904A2 (en) 1995-07-06
WO1995017904A3 true WO1995017904A3 (en) 1995-10-19
WO1995017904B1 WO1995017904B1 (en) 1995-12-07

Family

ID=22634387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/014717 Ceased WO1995017904A2 (en) 1993-12-28 1994-12-16 Botulinum toxins for treating various disorders and associated pain

Country Status (8)

Country Link
EP (23) EP1005867B2 (en)
JP (33) JP3238154B2 (en)
AU (1) AU688452B2 (en)
CA (2) CA2682117A1 (en)
DE (23) DE69434535T2 (en)
ES (18) ES2251651T3 (en)
FR (1) FR08C0034I1 (en)
WO (1) WO1995017904A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
ES2341140T3 (en) 1993-06-10 2010-06-15 Allergan, Inc. TREATMENT OF NEUROMUSCULAR DISORDERS AND AFFECTIONS WITH A DIFFERENT BOTULINIC SEROPOSITIVE.
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
DE69434535T2 (en) * 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxic component of botulinum toxins for modulating cholinergic-controlled secretions
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
ATE215832T1 (en) * 1994-05-09 2002-04-15 William J Binder BOTULINUM TOXIN FOR REDUCING MIGRAINE - HEADACHES
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
US6780413B2 (en) 1996-09-19 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
ATE320815T1 (en) 1997-07-15 2006-04-15 Univ Colorado USE OF NEUROTOXIN THERAPY TO TREAT PROSTATE DISEASES
AU2008201535C1 (en) * 1997-07-15 2013-09-12 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
AU2006225229B2 (en) * 1997-07-15 2006-12-07 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
WO1999037326A1 (en) 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19856897A1 (en) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic to suppress snoring noises
DE19925739A1 (en) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic with a botulinum neurotoxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6319506B1 (en) * 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
WO2002009743A1 (en) * 2000-08-02 2002-02-07 Allergan Sales, Inc. Method for treating a neoplasm
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (en) 2001-01-05 2002-07-05 Univ Degli Studi Udine USE OF BOTULIN TOXIN FOR THE SOLUTION OF JOINT PATHOLOGIES, IN PARTICULAR OF COXARTROSIS, EPICONDYLITIS AND PATHOLUS
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
JP2003009897A (en) 2001-07-03 2003-01-14 Keiji Oguma Separation and purification of botulinum toxin
KR20030018827A (en) * 2001-08-31 2003-03-06 서구일 Sympathetic nerve bl0cking agent comprising botulinum toxin type a, and composition for treatment of the sympathetic nerve related diseases
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
MXPA05003936A (en) * 2002-10-15 2005-06-17 Allergan Inc Botulinum toxin dental therapies and procedures.
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
NZ541779A (en) * 2003-03-06 2008-01-31 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US7335367B2 (en) 2003-03-06 2008-02-26 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2857595B1 (en) * 2003-07-18 2005-10-07 Sod Conseils Rech Applic USE OF BOTULINUM TOXIN FOR PREPARING A MEDICAMENT FOR PREVENTING OR TREATING AGONY-RELATED SOUND DISORDERS
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
CA2555939A1 (en) * 2004-02-12 2005-09-01 Philip Radovic Treatment of abnormalities of the first metatarsophalangeal joint of the foot
US7276244B2 (en) 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
HUE025656T2 (en) 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application of botulotoxins and transdermal delivery
EP1747782A1 (en) 2005-07-19 2007-01-31 Cesare Montecucco Products for topical application comprising lysophospholipids and fatty acids
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
FR2902341B1 (en) 2006-06-16 2011-02-25 Scras THERAPEUTIC USE SIMULTANEOUS, SEPARATE OR SPREAD IN THE TIME OF AT LEAST ONE BOTULINUM NEUROTOXIN, AND AT LEAST ONE OPIACEOUS DERIVATIVE
AR061669A1 (en) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
FR2907680B1 (en) 2006-10-27 2012-12-28 Scras THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN IN THE TREATMENT OF PAIN INDUCED BY AT LEAST ONE ANTI-CANCER AGENT
FR2910327B1 (en) 2006-12-22 2013-04-26 Scras USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING PAIN INDUCED BY THERAPEUTIC TREATMENTS OF AIDS VIRUS.
WO2008121067A1 (en) 2007-03-30 2008-10-09 Anders Fagergren Quantification of mechanical and neural contributions to spasticity
DK2178549T3 (en) 2007-07-26 2017-01-09 Revance Therapeutics Inc Antimicrobial peptide AND COMPOSITIONS THEREOF
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US8470337B2 (en) 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (en) 2008-04-25 2010-07-30 Sod Conseils Rech Applic THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR THE TREATMENT OF PAIN IN THE CASE OF DIABETIC NEUROPATHY
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
LT2379104T (en) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
CN102869373B (en) 2009-06-25 2017-05-10 雷文斯治疗公司 albumin-free botulinum toxin formulations
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
RU2545453C2 (en) * 2013-03-21 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method of treating mandibular fractures
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
KR101677710B1 (en) * 2014-06-30 2016-11-21 (주)메디톡스 Pharmaceutical composition for treating osteoarthritis comprising botulinum toxin as an active ingredient and method for treating osteoarthritis in a patient
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
JP7217700B2 (en) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド Stabilized non-protein Clostridial toxin composition
US11191819B2 (en) * 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
RU2732204C1 (en) * 2020-01-28 2020-09-14 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Gurov-levin method for treating tension-type headaches
CN116348480A (en) 2020-10-07 2023-06-27 普罗塔克斯公司 Vacuum drying method of botulinum toxin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
EP0654040A1 (en) * 1992-06-23 1995-05-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
WO1994015629A1 (en) * 1993-01-15 1994-07-21 Associated Synapse Biologics Method for treating myofascial pain syndrome
ES2341140T3 (en) * 1993-06-10 2010-06-15 Allergan, Inc. TREATMENT OF NEUROMUSCULAR DISORDERS AND AFFECTIONS WITH A DIFFERENT BOTULINIC SEROPOSITIVE.
EP0702559B1 (en) * 1993-06-10 2003-03-19 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
DE69434535T2 (en) * 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxic component of botulinum toxins for modulating cholinergic-controlled secretions
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE215832T1 (en) * 1994-05-09 2002-04-15 William J Binder BOTULINUM TOXIN FOR REDUCING MIGRAINE - HEADACHES
JP2001104991A (en) * 1999-10-12 2001-04-17 Toyoaki Kubota Organic substance removing agent for circulating water

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. BOGHEN ET AL.: "Effectiveness of Botulinum toxin in the treatment of spasmodic torticollis", EUR. NEUROL., vol. 33, pages 199 - 203, XP002025653 *
G. JENZER ET AL.: "Botulismus Typ B", SCHWEIZ. MED. WSCHR., vol. 104, pages 685 - 693, XP002972970 *
KONDO T., ET AL.: "Modification of the action of pentagastrin on acid secretion by botulinum toxin", EXPERIENTIA, vol. 33, no. 6, 15 June 1977 (1977-06-15), pages 750 - 751, XP000994885 *
N. HENESON: "Deadly toxin calms excited muscles", NEW SCIENTIST, no. 1746, 8 December 1990 (1990-12-08), pages 24, XP002025654 *
SAVINO P.J., ET AL: "hemifacial spasm treated with botulinum A toxin injection", ARCH. OPHTHALMOL., vol. 103, pages 1305 - 1306, XP000872408 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9314416B2 (en) 2005-03-03 2016-04-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins

Also Published As

Publication number Publication date
ES2207910T5 (en) 2010-05-21
JP2006160753A (en) 2006-06-22
DE69434319T2 (en) 2006-03-09
AU1516295A (en) 1995-07-17
EP1010431B1 (en) 2005-03-30
DE69428813T2 (en) 2002-04-04
HK1071071A1 (en) 2005-07-08
JP2002087984A (en) 2002-03-27
EP1790352B1 (en) 2008-07-09
JP2002087987A (en) 2002-03-27
HK1064599A1 (en) 2005-02-04
EP1563843B1 (en) 2013-08-07
JP3238154B2 (en) 2001-12-10
DE69435149D1 (en) 2008-11-20
EP1072270A3 (en) 2002-08-07
JP2010202661A (en) 2010-09-16
DE69434008D1 (en) 2004-10-21
EP1366770A3 (en) 2004-03-17
DE69434319D1 (en) 2005-05-04
EP1366770A2 (en) 2003-12-03
JP2013006865A (en) 2013-01-10
EP1072270A2 (en) 2001-01-31
EP1600163B1 (en) 2010-02-17
DE69434511T2 (en) 2006-07-13
ES2159624T3 (en) 2001-10-16
DE69427869T2 (en) 2002-04-11
DE69433394T3 (en) 2010-08-12
DE69434540D1 (en) 2009-03-26
JP2012167114A (en) 2012-09-06
DE122008000043I1 (en) 2008-11-20
ES2237033T3 (en) 2005-07-16
ES2332905T3 (en) 2010-02-15
DE69428813D1 (en) 2001-11-29
EP0770395A1 (en) 1997-05-02
JP2002068989A (en) 2002-03-08
DE69435321D1 (en) 2010-12-16
DE69434610D1 (en) 2008-08-21
EP1757325B1 (en) 2010-11-03
DE69433394T2 (en) 2004-10-14
CA2180011C (en) 2001-05-15
JP2008037877A (en) 2008-02-21
ES2355491T3 (en) 2011-03-28
JP2006160755A (en) 2006-06-22
EP1147775B1 (en) 2009-03-04
EP1488803A1 (en) 2004-12-22
ES2251651T3 (en) 2008-07-16
EP1005867B1 (en) 2003-12-03
EP1366771B1 (en) 2008-03-26
JP2006160754A (en) 2006-06-22
EP1591129B1 (en) 2010-02-24
JPH09507234A (en) 1997-07-22
EP1005867A2 (en) 2000-06-07
EP1147776A3 (en) 2003-01-15
JP2012188433A (en) 2012-10-04
EP1600163A1 (en) 2005-11-30
EP1757325A1 (en) 2007-02-28
EP1010431B2 (en) 2010-07-14
EP1005867B2 (en) 2010-02-17
JP2010202660A (en) 2010-09-16
DE69433394D1 (en) 2004-01-15
EP2027872B1 (en) 2010-07-14
ES2223393T3 (en) 2005-03-01
JP2002097156A (en) 2002-04-02
DE69435330D1 (en) 2011-01-27
EP1010431A2 (en) 2000-06-21
EP1421948A2 (en) 2004-05-26
EP1790352A1 (en) 2007-05-30
DE69435194D1 (en) 2009-04-16
EP1602379A1 (en) 2005-12-07
EP1488803B1 (en) 2008-03-26
DE69434511D1 (en) 2006-03-02
ES2339865T3 (en) 2010-05-26
JP2002087986A (en) 2002-03-27
EP1366770B1 (en) 2005-07-27
FR08C0034I1 (en) 2008-09-26
JP2006160756A (en) 2006-06-22
EP1366771A2 (en) 2003-12-03
ES2237033T5 (en) 2010-10-29
JP2002114706A (en) 2002-04-16
EP0737074A1 (en) 1996-10-16
EP0770395B1 (en) 2001-10-24
EP1147775A2 (en) 2001-10-24
DE69434540T2 (en) 2009-06-18
JP2012167117A (en) 2012-09-06
DE69435243D1 (en) 2009-11-19
DE69435302D1 (en) 2010-08-26
ES2248780T3 (en) 2008-06-16
DE69434535T2 (en) 2006-07-20
EP1477183B1 (en) 2005-11-02
EP1598077B1 (en) 2009-11-04
DE69434443D1 (en) 2005-09-01
EP1103267A1 (en) 2001-05-30
JP2002104990A (en) 2002-04-10
DE69434008T2 (en) 2005-09-22
DE69434610T2 (en) 2008-11-27
EP1010431A3 (en) 2001-05-16
DE122009000038I1 (en) 2009-11-05
HK1106700A1 (en) 2008-03-20
ES2334357T3 (en) 2010-03-09
EP1421948B1 (en) 2008-10-08
DE69435270D1 (en) 2010-04-01
CA2682117A1 (en) 1995-07-06
EP1366771A3 (en) 2003-12-10
EP1591129A3 (en) 2005-11-16
EP1147776A2 (en) 2001-10-24
EP1147775A3 (en) 2003-01-15
JP2002087985A (en) 2002-03-27
ES2163090T3 (en) 2002-01-16
EP1103267B1 (en) 2004-09-15
EP2027872A1 (en) 2009-02-25
WO1995017904A2 (en) 1995-07-06
ES2247575T3 (en) 2006-03-01
EP1502600B1 (en) 2009-10-07
HK1072375A1 (en) 2005-08-26
HK1033274A1 (en) 2001-08-24
DE122008000042I1 (en) 2009-01-02
JP2010209105A (en) 2010-09-24
ES2309973T3 (en) 2008-12-16
JP2012197287A (en) 2012-10-18
DE69427869D1 (en) 2001-09-06
DE69435276D1 (en) 2010-04-08
HK1070831A1 (en) 2005-06-30
CA2180011A1 (en) 1995-07-06
EP1147776B1 (en) 2010-12-15
EP1563843A1 (en) 2005-08-17
JP2010202659A (en) 2010-09-16
JP2008031176A (en) 2008-02-14
EP1005867A3 (en) 2001-06-13
JP2002087988A (en) 2002-03-27
ES2242126T3 (en) 2005-11-01
EP0737074B1 (en) 2001-08-01
EP1502600A1 (en) 2005-02-02
EP1421948A3 (en) 2004-06-16
ES2207910T3 (en) 2004-06-01
JP2002104991A (en) 2002-04-10
JP2008056682A (en) 2008-03-13
EP1477183A1 (en) 2004-11-17
DE69434535D1 (en) 2005-12-08
JP2008063339A (en) 2008-03-21
DE69434443T2 (en) 2006-05-24
EP1072270B1 (en) 2005-10-19
JP2012167116A (en) 2012-09-06
JP2007262086A (en) 2007-10-11
JP2012167115A (en) 2012-09-06
DE69435116D1 (en) 2008-08-21
JP2002097145A (en) 2002-04-02
DE69434319T3 (en) 2011-02-17
DE69435249D1 (en) 2009-12-17
ES2246800T3 (en) 2006-03-01
EP1486214A1 (en) 2004-12-15
AU688452B2 (en) 1998-03-12
EP1598077A1 (en) 2005-11-23
ES2347384T3 (en) 2010-10-28
ES2340172T3 (en) 2010-05-31
JP2008056683A (en) 2008-03-13
EP1591129A2 (en) 2005-11-02
ES2319860T3 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
CA2180011A1 (en) Botulinum toxins for treating sweating
WO1995017904B1 (en) Botulinum toxins for treating various disorders and associated pain
CA2310845A1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
CA2190011A1 (en) Method for Reduction of Headache Pain
CA2164626A1 (en) Multiple botulinum toxins for treating neuromuscular disorders and conditions
JP2004518632A5 (en)
EP2174662A3 (en) Methods for treating muscle injuries
EP1011695A4 (en) NEUROTOXIN-BASED THERAPY FOR THE TREATMENT OF UROLOGICAL DISORDERS AND RELATED DISORDERS
CA2168247A1 (en) Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
CA2061665A1 (en) Treatment of lower urinary tract disorders
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
WO2003070175A3 (en) Use of opioid compound to treat a neurologic or neurogenic disorder
CA2300703A1 (en) Method for treating excessive sweating
CA2589987A1 (en) Method for treating a cholinergic influenced secretion
CA2136953A1 (en) A method for using lipoprotein associated coagulation inhibitor to treat sepsis
WO1998001125A3 (en) Dextrorotatory isomers of oxybutynin and desethyloxybutynin in the treatment of gastrointestinal hyperactivity
WO1996029076A3 (en) Treatment of inflammatory bowel disorders with cotinine
WO1999065511A3 (en) Composition and method for treatment of pseudomonas infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1995906674

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2180011

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995906674

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995906674

Country of ref document: EP